Anti-Dupilumab Antibodies

s

s

s

Antibodies for bioanalysis and drug monitoring of dupilumab and biosimilars

Develop highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for the monoclonal antibody dupilumab (Dupixent) using our range of ready-made antibodies.

• Recombinant antibodies specific to dupilumab and dupilumab-IL4Rα complex
• TrailBlazer Antibodies enabling site-directed conjugation and format switching
• Fully human surrogate positive control or calibrator
• Sequence-defined, well-characterized reagents with a secure supply
• Stringent quality control for batch-to-batch consistency

Table 1. Antibodies Specific to Dupilumab and Dupilumab-IL4Rα complex.

* Affinity measured in the monovalent Fab format
¹ Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags
² Fab2-FH-X22-HRP = Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags, and Fab-SpyTag coupled to HRP conjugated BiCatcher

Anti-Dupilumab Inhibitory Antibodies (Type 1)

Type 1 anti-dupilumab antibodies inhibit the binding of the drug dupilumab to its target, interleukin-4 subunit α (IL-4Rα) receptor. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.

Anti-Dupilumab Non-Inhibitory Antibodies (Type 2)

The type 2 anti-dupilumab antibodies bind to the dupilumab idiotope, but do not inhibit the binding of dupilumab to IL-4Rα. They are ideal for development of a PK bridging ELISA to measure total dupilumab (free and IL-4Rα bound dupilumab). 

Anti-Dupilumab/IL-4Rα Complex Specific Antibody (Type 3)

The type 3 antibody specifically recognizes the drug-target complex, detecting dupilumab only when it is bound to IL-4Rα. It is suitable as a detection antibody in a PK antigen capture assay.

TrailBlazer Antibodies

TrailBlazer™ Antibodies, clones TZA014 AbD47091ad (Type 1), TZA015 AbD47092ad (Type 1), TZA016 AbD48333ad (Type 2), TZA017 AbD48542ad (Type 2), and TZA054 AbD48337ad (Type 3) have a SpyTag2 incorporated at the C-terminus of the antibody heavy chain. In a fast reaction that simply requires mixing at room temperature, these antibodies can form a covalent isopeptide bond to a SpyCatcher reagent, enabling site-directed conjugation or fast conversion to a bivalent Fab or a full-length Ig-like format within an hour.

ELISA Protocols to Get You Started

PK Bridging ELISA

Fig. 1. Dupilumab PK bridging ELISA using antibodies TZA014 and TZA015P.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.

Fig. 2. Dupilumab PK bridging ELISA using antibodies TZA016 and TZA017P.

Schematic image of PK bridging ELISA detecting total drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP. Note for dupilumab Type 2 antibodies, the detection antibody is in Fab format.

PK Antigen Capture ELISA

Fig. 3. Dupilumab PK antigen capture ELISA using antibody TZA054.

Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), labeled with HRP.

ADA Bridging ELISA

Fig. 4. Dupilumab ADA bridging ELISA using antibodies HCA383 and HCA384.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Resources

Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.